Literature DB >> 4039782

Cholinergic agents: antinociception without morphine type dependence in rats.

M Widman, S Tucker, D A Brase, W L Dewey.   

Abstract

We have confirmed the work of others showing that loss in body weight is a predictable and consistent sign of opiate withdrawal in rats. Rats that were treated chronically with either oxotremorine or physostigmine displayed no weight loss or other signs of opiate-like withdrawal when the drugs were withdrawn. Furthermore, there was no difference in weight loss between morphine dependent rats substituted with saline and those substituted with either cholinergic drug. However, we did observe an increased mortality among rats substituted with a cholinergic agent compared with saline. Rats infused with a mixture of morphine plus oxotremorine or morphine plus physostigmine showed less weight loss, but not fewer behavioral signs, after the end of the infusion than rats treated only with morphine. It is concluded that the cholinergic agents did not cause a morphine-like physical dependence themselves, but appeared to antagonize to some extent the development or manifestation of opiate dependence.

Entities:  

Mesh:

Substances:

Year:  1985        PMID: 4039782     DOI: 10.1016/0024-3205(85)90450-3

Source DB:  PubMed          Journal:  Life Sci        ISSN: 0024-3205            Impact factor:   5.037


  3 in total

1.  Pronounced pharmacologic deficits in M2 muscarinic acetylcholine receptor knockout mice.

Authors:  J Gomeza; H Shannon; E Kostenis; C Felder; L Zhang; J Brodkin; A Grinberg; H Sheng; J Wess
Journal:  Proc Natl Acad Sci U S A       Date:  1999-02-16       Impact factor: 11.205

Review 2.  New pharmacological approaches to the cholinergic system: an overview on muscarinic receptor ligands and cholinesterase inhibitors.

Authors:  Nigel H Greig; Marcella Reale; Ada M Tata
Journal:  Recent Pat CNS Drug Discov       Date:  2013-08

Review 3.  Care pathways for glaucoma detection and monitoring in the UK.

Authors:  Robert A Harper; Patrick J G Gunn; Paul G D Spry; Cecilia H Fenerty; John G Lawrenson
Journal:  Eye (Lond)       Date:  2019-11-07       Impact factor: 3.775

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.